A Study to Evaluate the Drug Levels, Safety, and Tolerability of BMS-986036 in Participants With Normal Liver Function and Participants With Moderate and Severe Liver Impairment

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 23, 2020

Primary Completion Date

June 2, 2022

Study Completion Date

June 2, 2022

Conditions

Moderate Liver ImpairmentSevere Liver Impairment

Interventions

DRUG

BMS-986036

Specified dose on specified days

Trial Locations (3)

Local Institution, Orlando

Local Institution - 0002, Miami

Local Institution - 0001, San Antonio